QualityDipStocks / Health Care · Medical Specialities
Guardant Health GH
Outside our quality screen, so we don’t track its dips. It’s 4% below its 52-week high.
Outside our quality screen, 6% over its Market Value. No fair value estimate for now: its free cash flow is negative.
- Fair value est.
- n/a
- Market Value
- $167.98price +6%
- Off 52-wk high
- −4%
- Risk vs market
- Market-likebeta 1.04
4 bullish · 5 bearish See why
Key levels
Every level vs today’s $178.80
- 52-wk lowlowest close, 1 year$78.60−56.0%
- Market Valueavg paid since Jul 30$167.98−6.1%
- PriceFri Oct 30 close$178.80you are here
- 52-wk highhighest close, 1 year$187.22+4.7%
Fair value estimate
No estimate for GH: negative free cash flow. We’d rather show nothing than a made-up number.
Risk vs market
How risk vs market is measured
One year of daily returns (Oct 30 to Oct 30, 252 sessions). Beta = how much GH moved for each 1% move in the S&P 500 (SPY); 1.0 moves with the market. Volatility is the yearly standard deviation of daily returns. Past behavior, not a forecast.
Moves about in line with the market, and its own price swings are 4.6× the S&P 500’s.
- Beta vs S&P 500
- 1.04
- Volatility
- 59% vs 13% SPY
- Correlation SPY
- 0.23
- Correlation QQQ
- 0.21
Bull vs bear
Rule-based from the data on this page, strongest first. Not advice.
Top bullish points 4 of 5
ProfitabilityOperating margin widened to −44.5% in FY2025 from −100.1% in FY2023 (SEC filings).
GrowthSales grew 43% to $1.2B over the last 12 months vs the 12 months before (SEC filings).
GrowthSales compounded 30% a year from FY2022 to FY2025.
ProfitabilityGross margin widened to 64.5% in FY2025 from 59.7% in FY2023 (SEC filings).
Top bearish points 5 of 5
ValuationFree cash flow is negative (−$241M over the last 12 months), so there’s no cash-flow value under the price.
Balance sheetOperating income covers interest only -97.6× over the last 12 months.
ProfitabilityLost $453M over the last 12 months (net income, SEC filings).
ProfitabilityLoses money at the operating line: −40% operating margin over the last 12 months.
QualityDoesn’t pass our quality screen: no positive free cash flow; ROE under 12% and ROIC under 10%; debt load unclear or high.
Who’s talking about it
Notable investors, executives, analysts and public figures on Guardant Health in the last 48 hours. Headlines as published, each linked. Their words, not ours.
No notable mentions in the last 48 hours. Checked Nov 1, 9:09 PM ET.
Compare with peers
Closest in size in Medical Specialities
All fundamentals
FCF yield -1.0% · Sales +43%
Valuation
- P/E
- n/aloss over the last 12 months
- Price / FCF
- n/anegative free cash flow
- FCF yield
- −1.0%
- EV / EBITDA
- n/anegative EBITDA
- Price / sales
- 21.05×
- Price / book
- n/anot reported in its SEC filings
- Market cap
- $24.9Blisted
- Enterprise value
- $25.3B
Growth
- Revenue, 12 months
- $1.2B
- Sales growth, 12 months
- +42.7%vs the 12 months before
- Sales growth, 3 yrs
- +29.8%/yrfrom FY2022
- Diluted EPS, 12 months
- −$3.51
- EPS growth, last FY
- n/afewer than two years of diluted EPS
- Net income, 12 months
- −$453M
- Net income growth
- n/anot reported in its SEC filings
Profitability
- Gross margin
- 65.0%
- Operating margin
- −39.7%
- Net margin
- −38.3%
- FCF margin
- −20.3%
- Return on equity
- n/anegative shareholder equity
- Return on invested capital
- −164%
Balance sheet
- Cash & short-term inv.
- $1.1B
- Total debt
- $1.5B
- Net cash
- −$449M
- Debt / equity
- n/adebt or equity not tagged in SEC data
- Interest coverage
- -97.6×operating income / interest
Cash flow & returns
- Free cash flow, 12 months
- −$241M
- FCF growth, 12 months
- n/anot reported in its SEC filings
- Dividend yield
- 0%
- Payout ratio
- n/anot reported in its SEC filings
- Buybacks, 12 months
- $0
- Share count, 1 year
- +7.1%diluted shares vs a year ago
- Stock-based comp
- $191M
Trailing 12 months to Jun 30, 2026; balance sheet at Jun 30, 2026. From Guardant Health’s SEC filings. Sparklines show up to six fiscal years. n/a means we don’t hold that number, with the reason. How each is computed.
Valuation details
MV $167.98
Setup & signals
No setup armed
No setup armed, so there’s no trigger or stop to track yet. Reversal signal rules only run on companies that pass our quality screen.
Momentum & 52-week range
RSI 57 · 5 days +5.7%
The business
FCF $-0.2B · Sales +44%
- Free cash flow, 12 months−$0.2B
- Free-cash-flow yield−1.0%
- Free-cash-flow margin−20%
- Gross margin65%
- Operating margin−40%
- Return on invested capital−29%
- Sales growth (latest quarter vs year-ago quarter)+44%
Next report
Nov 5
- DateThu Nov 5, after the close
- Consensus EPS($0.68)
- Year-ago EPS($0.74)
- QuarterSep/2026
From Nasdaq’s earnings calendar. A report resets Market Value.
Information only, not investment advice. Fair value estimates and talking points are rule-based model output from public data and can be wrong; stop levels are reference points, not orders. How every number is computed.
GH is outside our quality screen
One text when a published rule fires on one of the 333 quality companies we track: the ticker, the price, the stop and a link to the numbers. Nothing else.